Cancer Discov. 2019 Sep;9(9):1150-1151. doi: 10.1158/2159-8290.CD-NB2019-085. Epub 2019 Jul 22.
The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data.
美国食品药品监督管理局(FDA)加速批准了塞利尼索联合低剂量地塞米松用于治疗三重耐药性多发性骨髓瘤,尽管一个顾问小组对该药物的毒性以及缺乏随机临床数据表示担忧。